AVIR
Companies
NASDAQ
Atea Pharmaceuticals Inc.
Health Care
$3.32
-$0.04 (-1.04%)
Price Chart
Overview
About AVIR
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Market Cap
$311.6M
Volume
1.6M
Avg. Volume
1.6M
P/E Ratio
-1.7908497
Dividend Yield
0.00%
Employees
67.0
Company Information
Latest News for AVIR
Risk & Correlation Analysis
Market Correlation
0.53
Low Correlation
Volatility
High (0.46)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, AVIR shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$311.6M
Volume1.6M
P/E Ratio-1.79
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025